Advertisement

Increased expression of biological markers as potential therapeutic targets in Saudi women with triple-negative breast cancer

Abstract

Aims and background. Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that lacks the expression of hormone receptors and human epidermal growth factor receptor 2 (HER2). Although TNBC represents only 15% of all types of breast cancer, it accounts for a large number of metastatic cases and deaths. Because of the high metastatic rate and both local and systemic recurrence associated with TNBC, extensive research efforts are actively looking for target therapies to effectively treat this aggressive disease. Accordingly, this study has been initiated to investigate the differential expression of biological markers in TNBC and non-TNBC Saudi women that might be utilized as potential targeted therapy and/or predict the sensitivity to currently available therapeutic regimens.
Methods and study design. Two hundred formalin-fixed, paraffin-embedded (FFPE) breast cancer tissues were selected and divided into 3 groups: benign breast tissues (20), TNBC tissues (80) and non-TNBC tissues (100). Expression of mRNA in FFPE tissues was analyzed using real-time polymerase chain reaction (RT-PCR) for the following genes: poly (ADP-ribose) polymerase 1 (PARP-1), topoisomerase 2A (TOPO- 2A), vascular endothelial growth factor (VEGF), C-MYC, basic fibroblast growth factor (bFGF), matrix metalloproteinases (MMP-2 and MMP-9), human epidermal growth factor 1 (HER1) and multidrug resistance (MDR) genes.
Results. In the TNBC group, expression of PARP-1, TOPO-2A, HER1, C-MYC, VEGF, bFGF and MMP-2 showed a highly significant increase compared to the non-TNBC group.
Conclusions. The results of this study suggest that (1) TNBC patients will benefit more from TOPO-2A inhibitors as well as antiangiogenic and antimetastatic therapies; (2) inhibition of these target genes is emerging as one of the most exciting and promising targeted therapeutic strategies to treat TNBC in which the intended targets are DNA repair, tumor angiogenesis and metastasis.

Tumori 2013; 99(4): 545 - 554

Article Type: ORIGINAL RESEARCH ARTICLE

DOI:10.1700/1361.15109

Authors

Mohamed Mohamed Sayed-Ahmed, Mohamed Mahmoud Hafez, Othman Abdualla Al-Shabanah, Salim Salih Al-Rejaie, Abdulaziz Mohamed Aleisa, Abdulaziz Abdulrhman Al-Yahya, Abdulmalik Alsheikh, Abdurrahman Ibrahim Al Diab, Mohammad Hamad Al-Akeely

Article History

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

  • Sayed-Ahmed, Mohamed Mohamed [PubMed] [Google Scholar]
    Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia
  • Hafez, Mohamed Mahmoud [PubMed] [Google Scholar]
    Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia
  • Al-Shabanah, Othman Abdualla [PubMed] [Google Scholar]
    Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia
  • Al-Rejaie, Salim Salih [PubMed] [Google Scholar]
    Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia
  • Aleisa, Abdulaziz Mohamed [PubMed] [Google Scholar]
    Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia
  • Al-Yahya, Abdulaziz Abdulrhman [PubMed] [Google Scholar]
    Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia
  • Alsheikh, Abdulmalik [PubMed] [Google Scholar]
    Department of Pathology, King Saud University, Riyadh, Kingdom of Saudi Arabia
  • Al Diab, Abdurrahman Ibrahim [PubMed] [Google Scholar]
    Oncology Division, Department of Internal Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia
  • Al-Akeely, Mohammad Hamad [PubMed] [Google Scholar]
    Department of Surgery, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.